Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes (Q38455771)

3 September 2017

1 reference

title

Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes (English)

1 reference

3 September 2017

1 reference

1 reference

André J Scheen

1

1 reference

PubMed ID

25936384

3 September 2017

language of work or name

English

0 references

publication date

2 May 2015

1 reference

Expert Opinion on Drug Metabolism & Toxicology

3 September 2017

1 reference

3 September 2017

11

1 reference

3 September 2017

1005-1020

1 reference

3 September 2017

6

1 reference

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

3 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pioglitazone: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

A review of gliptins in 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

A review of gliptins for 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Alogliptin benzoate for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

The pharmacokinetics of pioglitazone in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetic interactions with thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Enhancing pancreatic Beta-cell regeneration in vivo with pioglitazone and alogliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pioglitazone and cancer: angel or demon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pioglitazone: side effect and safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Hepatotoxicity with thiazolidinediones: is it a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Thiazolidinediones and the liver in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Outcomes and lessons from the PROactive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

National Cholesterol Education Program and International Diabetes Federation definitions of metabolic syndrome in the prediction of diabetes. Results from the FIrenze-Bagno A Ripoli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Combine and conquer: advantages and disadvantages of fixed-dose combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Metformin + saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

SGLT2 versus DPP4 inhibitors for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1041499

10.1517/17425255.2015.1041499

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

25936384